Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must carry at least one of certain specific genetic tissue markers (called HLA types: A2, A24, A33, B35, B49, or CW04/12) — the trial team will test for these (confirm with trial site).
- You have been diagnosed with skin melanoma that is at a certain stage of seriousness (thick tumors over 4mm, or ulcerated tumors over 4mm).
- You have melanoma that has spread to nearby lymph nodes and those lymph nodes have been surgically removed.
- You have melanoma that has spread to distant parts of the body but has been completely removed by surgery.
- You have melanoma that has spread but cannot be fully removed by surgery, your disease is at a low level, your LDH blood levels are normal, and you have already tried at least two types of treatment (confirm with trial site).
- You have a non-skin form of melanoma, such as eye (uveal) or mucosal melanoma, at the relevant stages.
- Your melanoma can have either the BRAF gene mutation or not — both are eligible.
- You are generally well enough to carry out normal activities, even if some effort is required (Karnofsky score above 80).
- You do not have any active heart or breathing conditions.
- You are not pregnant or breastfeeding, and women must use contraception during treatment.
- Your basic blood count results (red and white blood cells) meet minimum levels.
- You are willing and able to give your informed consent to participate.
Who may not be able to join:
- You have received chemotherapy or extensive radiotherapy within the last 28 days.
- You have active cancer that has spread to the brain and currently requires steroid medication to manage it.
- You have another active cancer at the same time (except certain minor skin cancers, early-stage cervical abnormalities, or early-stage prostate cancer).
- You have a serious active infection.
- You have an allergy to penicillin.
- You do not wish to continue participating in the study.
- You are a carrier of HIV, or have chronic Hepatitis B or Hepatitis C.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 972507874292
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
grade 2-4 adverse events according to CTCEA criteria; monitoring anti-tumor immune response; grade 2-4 adverse events according to CTCEA criteria; grade 2-4 adverse events according to CTCEA criteria; grade 2-4 adverse events according to CTCEA criteria; grade 2-4 adverse events according to CTCEA criteria; grade 2-4 adverse events according to CTCEA criteria; grade 2-4 adverse events according to CTCEA criteria; monitoring anti-tumor immune response; monitoring anti-tumor immune response; monitoring anti-tumor immune response; monitoring anti-tumor immune response; monitoring anti-tumor immun...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.